Top

Orphanet Journal of Rare Diseases

Published in:

Open Access 01-12-2018 | Letter to the Editor

MicroRNAs are appropriate in mitochondrial related hearing loss? Answer to the skepticism

Authors: Arianna Di Stadio, Corrado Angelini

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Abstract

Aim

We aim to clarify some points that have been criticized about our previous paper “Hearing Impairment in MELAS: new prospective in clinical use of microRNA, a systematic review”.

Material and method

We answered to the criticism of Dr. Finsterer point by point, by citing all literature in support of our previous paper.

Conclusion

The point by point answering allows us to clarify doubts and to support the proposal that we exposed in our review, the possibility to use microRNA for detecting the hearing damage in patients affected from mitochondrial disease.

Di Stadio A, Pegoraro V, Giaretta L, Dipietro L, Marozzo R, Angelini C. Hearing impairment in MELAS: new prospective in clinical use of microRNA, a systematic review. Orphanet J Rare Dis. 2018 Feb 21;13(1):35.CrossRefPubMedPubMedCentral

Egger M, Altman DG, Smith GD. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. p. 410–8.

Loganantharaj R, Randall TA. The limitations of existing approaches in improving MicroRNA target prediction accuracy. Methods Mol Biol. 2017;1617:133–58. https://doi.org/10.1007/978-1-4939-7046-9_10.CrossRefPubMed

Xue T, Wei L, Zha DJ, Qiu JH, Chen FQ, Qiao L, Qiu Y. miR-29b overexpression induces cochlear hair cell apoptosis through the regulation of SIRT1/PGC-1αsignaling: implications for age-related hearing loss. Int J Mol Med. 2016;38(5):1387–94.CrossRefPubMedPubMedCentral

K T, Merchant SN, Miyazawa T, Yamaguchi T, McKenna MJ, Kouda H, Iino Y, Someya T, Tamagawa Y, Takiyama Y, Nakano I, Saito K, Boyer P, Kitamura K. Temporal bone histopathological and quantitative analysis of mitochondrial DNA in MELAS. Laryngoscope. 2003;113(8):1362–8.CrossRef

Koda H, Kimura Y, Ishige I, Eishi Y, Iino Y, Kitamura K. Quantitative cellular level analysis of mitochondrial DNA 3243A > G mutations in individual tissues from the archival temporal bones of a MELAS patient. Acta Otolaryngol. 2010;130(3):344–50.CrossRefPubMed

Wilichowski E. Progressive sensorineural hearing loss in children with mitochondrial encephalomyopathies. Laryngoscope. 2001;111(3):515–21.CrossRefPubMed

Santarelli RM, Cama E, Scimeni P, La Morgia C, Caporali L, Valentino ML, Liguori R, Carelli V. Reply: both mitochondrial DNA and mitonuclear genemutations can cause hearing loss through cochlear dysfunction. Brain 2016;140:1–5.el.

Meseguer S, Martínez-Zamora A, García-Arumí E, Andreu AL, Armengod ME. The ROS-sensitive microRNA-9/9* controls the expression of mitochondrial tRNA-modifying enzymes and is involved in the molecular mechanism of MELAS syndrome. Hum Mol Genet. 2015;24(1):167–84.CrossRefPubMed

Title: MicroRNAs are appropriate in mitochondrial related hearing loss? Answer to the skepticism
Authors: Arianna Di Stadio
Corrado Angelini
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-018-0865-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

MicroRNAs are appropriate in mitochondrial related hearing loss? Answer to the skepticism

Abstract

Aim

Material and method

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aim

Material and method

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Gastro-oesophageal reflux - an important causative factor of severe tooth wear in Prader-Willi syndrome?

Recommendations for the design of small population clinical trials

The European challenges of funding orphan medicinal products

Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study

Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study

Comorbidity among HHT patients and their controls in a 20 years follow-up period